Image Source: Unsplash

AbCellera Biologics (ABCL), a constituent in the MunAiMarkets Ai-Focused Drug Discovery Stocks Portfolio, saw a significant price increase in the week ending June 6th, with its stock rising 20.8%. Here's why.

1. Several hedge funds and other institutional investors have recently added to their stakes in the business, namely, Moloney Securities, State of New Jersey Common Pension Fund D, Raymond James Financial, HighTower Advisors LLC and IMG Wealth Management. 61.42% of the stock is currently owned by institutional investors.
2. AbCellera is approaching a potential inflection point as it advances two new molecules—ABCL575 and ABCL635—into clinical trials, signaling its progress from a platform with promise to one capable of solving real-world medical problems.
   • ABCL575 targets the OX-40 pathway, a critical immune regulator, and is being trialed for atopic dermatitis, with broader implications for treating alopecia and other chronic conditions that often stem from underlying viral or bacterial infections and
   • ABCL635 is in preclinical trial to treat metabolic and endocrine conditions.

About AbCellera Biologics

Headquartered in Vancouver, Canada, AbCellera engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States with a research collaboration and license agreement with Eli Lilly and Company; and partnership agreements with Biogen Inc., Viking Global Investors & ArrowMark . 

Stock Price Forecast/Rating

According to 3 professional analysts, their average price target of $8.33 for AbCellera represents a 241% increase in the stock price over the next year and rate the company as a "Strong Buy" meaning that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

More By This Author:

Cannabis Company, Tilray Brands, Planning A Major Reverse Stock Split - Here's Why
AI-Focused Recursion Pharmaceuticals Stock Jumped 31% Last Week; Here's Why
Tesla Stock Dropped 14.5% Last Week; Now Down 28% YTD - Here's Why